Koers VG Life Sciences Inc. Other OTC
Aandelen
VGLS
US91822T1016
Biotechnologie & Medisch Onderzoek
Omzet 2013 | - | Omzet 2014 | - | Marktkapitalisatie | 2,23 mln. 2,07 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2013 | -7 mln. -6,52 mln. | Nettowinst (verlies) 2014 | -6 mln. -5,58 mln. | EV/omzet 2013 | - |
Nettoschuld 2013 | 2,49 mln. 2,32 mln. | Nettoschuld 2014 | 3,83 mln. 3,56 mln. | EV/omzet 2014 | - |
K/w-verhouding 2013 |
-0,25
x | K/w-verhouding 2014 |
-0,31
x | Werknemers | - |
Dividendrendement 2013 * |
-
| Dividendrendement 2014 |
-
| Vrij verhandelbaar | 100% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Ana Gois
IRC | Investor Relations Contact | - | - |
Corporate Officer/Principal | - | - |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Paul Stricklandd
BRD | Director/Board Member | 48 | 01-01-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+34,01% | 51,07 mld. | |
+33,84% | 38,86 mld. | |
-8,02% | 38,78 mld. | |
-8,98% | 26,69 mld. | |
+12,56% | 26,35 mld. | |
-19,62% | 19,46 mld. | |
+39,18% | 13,58 mld. | |
+31,47% | 12,46 mld. | |
-3,40% | 11,75 mld. |